Targeting tumor necrosis factor receptors in ankylosing spondylitis
Abstract
Over the past two decades, considerable advances in our understanding of inflammatory and immune pathways have allowed for the growing use of targeted biologic therapy. Most notably, the introduction of tumor necrosis factor (TNF) inhibitors has dramatically changed the management of autoimmune inflammatory disorders, including ankylosing spondylitis (AS). Despite the efficacy of TNF inhibitors documented in multiple clinical trials, anti‐TNF therapy in AS is far from foolproof; it is associated with serious adverse effects and limited response to therapy in some patients. Moreover, specific questions regarding the role of TNF as a mediator of AS remain unanswered. Therefore, additional efforts are needed in order to better understand the role of TNF in the pathogenesis of AS and to develop safer and more effective treatment strategies. The purpose of this review is to better the understanding of the physiologic and pathogenic roles of TNF signaling in the course of AS. Relevant TNF biology and novel approaches to TNF blockade in AS are discussed.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 15, 2018
- Source ID
- 10.1111/nyas.13933
Entities
People
- Aubryanna Hettinghouse
- Chuan‐ju Liu
- Michal Lata
Organizations
- NYU Langone Health
- National Institutes of Health
- New York University
- United States Department of Defense